Response to: 'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang

被引：7

作者：

Wei, James Cheng-Chung ^{[1
,2
,3
,4
]}

Kim, Tae-Hwan ^{[5
]}

Kishimoto, Mitsumasa ^{[6
]}

Ogusu, Naoki ^{[7
]}

Jeong, Haeyoun ^{[8
]}

Kobayashi, Shigeto ^{[9
]}

机构：

[1] Chung Shan Med Univ Hosp, Dept Allergy Immunol & Rheumatol, Taichung, Taiwan

[2] Chung Shan Med Univ, Inst Med, Coll Med, Taichung, Taiwan

[3] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan

[4] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan

[5] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea

[6] Kyorin Univ Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan

[7] Kyowa Kirin Co Ltd, Clin Dev Ctr, Tokyo, Japan

[8] Kyowa Kirin Korea Co Ltd, Dev Dept, Seoul, South Korea

[9] Juntendo Univ Koshigaya Hosp, Dept Internal Med & Rheumatol, Saitama, Japan

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 07期

关键词：

ankylosing; biological therapy; inflammation; spondylitis; therapeutics;

D O I：

10.1136/annrheumdis-2021-220788

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页数：2

共 6 条

[1] FDA, 2017, SILIQ BROD INJ SUBC
[2] Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M.
Strober, B.
Menter, A.
Gordon, K.
Weglowska, J.
Puig, L.
Papp, K.
Spelman, L.
Toth, D.
Kerdel, F.
Armstrong, A. W.
Stingl, G.
Kimball, A. B.
Bachelez, H.
Wu, J. J.
Crowley, J.
Langley, R. G.
Blicharski, T.
Paul, C.
Lacour, J. -P.
Tyring, S.
Kircik, L.
Chimenti, S.
Duffin, K. C.
Bagel, J.
Koo, J.
Aras, G.
Li, J.
Song, W.
Milmont, C. E.
Shi, Y.
Erondu, N.
Klekotka, P.
Kotzin, B.
Nirula, A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (14) : 1318 - 1328
[3] Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Mease, Philip J.
Helliwell, Philip S.
Hjuler, Kasper Fjellhaugen
Raymond, Kyle
McInnes, Iain
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (02) : 185 - 193
[4] Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
Ruiz de Morales, Jose Maria G.
Puig, Lluis
Dauden, Esteban
Canete, Juan D.
Luis Pablos, Jose
Olveira Martin, Antonio
Gonzalez Juanatey, Carlos
Adan, Alfredo
Montalban, Xavier
Borruel, Natalia
Orti, Guillermo
Holgado-Martin, Esther
Garcia-Vidal, Carolina
Vizcaya-Morales, Cynthia
Martin-Vazquez, Victor
Angel Gonzalez-Gay, Miguel
[J]. AUTOIMMUNITY REVIEWS, 2020, 19 (01)
[5] Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
Wei, James Cheng-Chung
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Ogusu, Naoki
Jeong, Haeyoun
Kobayashi, Shigeto
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (08) : 1014 - 1021
[6] Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial'
Zhao, Yan
Huang, Jin-Xian
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (07)

← 1 →